{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T13:31:47Z","timestamp":1793712707879,"version":"4.6.1"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Institute of Allergy and Infectious Diseases of the National Institutes of Health","award":["UM1AI068636"],"award-info":[{"award-number":["UM1AI068636"]}]},{"name":"National Institute of Allergy and Infectious Diseases of the National Institutes of Health","award":["UM1AI068634"],"award-info":[{"award-number":["UM1AI068634"]}]},{"name":"National Institute of Allergy and Infectious Diseases of the National Institutes of Health","award":["UM1AI106701"],"award-info":[{"award-number":["UM1AI106701"]}]},{"DOI":"10.13039\/501100005612","name":"Shionogi & Co., Ltd.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Ensitrelvir, a severe acute respiratory syndrome coronavirus-2 main protease inhibitor, has demonstrated clinical and virologic efficacy in previous studies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In this global phase 3 trial, nonhospitalized adults with mild-to-moderate coronavirus disease 2019 (COVID-19) and symptom onset within 5 days were randomized (1:1) to receive once-daily ensitrelvir (375\u2005mg day 1, 125\u2005mg days 2\u20135) or blinded matching placebo. The primary endpoint was the restricted mean time to sustained (\u22652 days) resolution of 15 COVID-19 symptoms, recorded in participant daily diaries, through day 29 in participants starting treatment within 3 days after symptom onset. Virologic efficacy and safety were assessed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 2093 participants, 1888 started treatment within 3 days after symptom onset. Mean time to symptom resolution was 12.5 and 13.1 days with ensitrelvir and placebo, respectively (difference, \u22120.6 days; 95% confidence interval, \u22121.38 to 0.19; P = .14). On day 4, ensitrelvir reduced least-squares mean RNA by 0.72 log10 copies\/mL more than placebo (95% confidence interval, 0.55\u20130.90). Among those with positive viral cultures at enrollment, 274\/287 (95.5%) ensitrelvir-treated versus 210\/280 (75.0%) placebo-treated participants had negative cultures on day 4. RNA rebound was similar (&amp;lt;1.5%) between groups. The proportion of participants with \u22651 adverse event was similar with ensitrelvir (61.5%) and placebo (60.6%). No treatment-related serious adverse events or deaths occurred. Three (0.3%) ensitrelvir-treated and 1 (0.1%) placebo-treated participants had COVID-19\u2013related hospitalizations by day 29.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Despite the evidence of antiviral activity with ensitrelvir, this trial did not demonstrate a significant difference in time to sustained symptom resolution.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Trials Registration Number<\/jats:title>\n                  <jats:p>NCT05305547.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciaf029","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T06:56:42Z","timestamp":1739775402000},"page":"1235-1244","source":"Crossref","is-referenced-by-count":23,"title":["Ensitrelvir for the Treatment of Nonhospitalized Adults with COVID-19: Results from the SCORPIO-HR, Phase 3, Randomized, Double-blind, Placebo-Controlled Trial"],"prefix":"10.1093","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0911-1578","authenticated-orcid":false,"given":"Anne F","family":"Luetkemeyer","sequence":"first","affiliation":[{"name":"Division of HIV, Infectious Diseases and Global Medicine, Zuckerberg San Francisco General, University of California San Francisco , San Francisco, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4865-4348","authenticated-orcid":false,"given":"Kara W","family":"Chew","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles , Los Angeles, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Lacey","sequence":"additional","affiliation":[{"name":"Biostatistics, Shionogi B.V. , London ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D","family":"Hughes","sequence":"additional","affiliation":[{"name":"Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3170-0865","authenticated-orcid":false,"given":"Linda J","family":"Harrison","sequence":"additional","affiliation":[{"name":"Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1880-7331","authenticated-orcid":false,"given":"Eric S","family":"Daar","sequence":"additional","affiliation":[{"name":"Division of HIV Medicine, Lundquist Institute at Harbor University of California Los Angeles , Torrance, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Eron","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3703-7849","authenticated-orcid":false,"given":"Courtney V","family":"Fletcher","sequence":"additional","affiliation":[{"name":"UNMC Center for Drug Discovery, University of Nebraska Medical Center , Omaha, Nebraska ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7443-0527","authenticated-orcid":false,"given":"Alexander L","family":"Greninger","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, University of Washington , Seattle, Washington ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Hessinger","sequence":"additional","affiliation":[{"name":"National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9914-9662","authenticated-orcid":false,"given":"Jonathan Z","family":"Li","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital, Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Mailhot","sequence":"additional","affiliation":[{"name":"National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7764-0212","authenticated-orcid":false,"given":"David","family":"Wohl","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4582-4914","authenticated-orcid":false,"given":"Methee","family":"Chayakulkeeree","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Tropical Medicine, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University , Bangkok ,","place":["Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Luis Accini","family":"Mendoza","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, IPS Centro Cientifico Asistencial S.A.S. , Barranquilla ,","place":["Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Polina","family":"Elistratova","sequence":"additional","affiliation":[{"name":"Clinical Development, Shionogi Inc. , Florham Park, New Jersey ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluwaseun","family":"Makinde","sequence":"additional","affiliation":[{"name":"Clinical Development, Shionogi Inc. , Florham Park, New Jersey ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth","family":"Morgan","sequence":"additional","affiliation":[{"name":"Portfolio Management, Shionogi Inc. , Florham Park, New Jersey ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9853-4160","authenticated-orcid":false,"given":"Simon","family":"Portsmouth","sequence":"additional","affiliation":[{"name":"Clinical Development, Shionogi Inc. , Florham Park, New Jersey ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5853-9426","authenticated-orcid":false,"given":"Takeki","family":"Uehara","sequence":"additional","affiliation":[{"name":"Drug Development and Regulatory Science Division, Shionogi & Co., Ltd. , Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3603-1733","authenticated-orcid":false,"given":"Davey","family":"Smith","sequence":"additional","affiliation":[{"name":"Antiviral Research Center, University of California , San Diego, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4279-4737","authenticated-orcid":false,"given":"Judith S","family":"Currier","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles , Los Angeles, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,17]]},"reference":[{"key":"2025071809220235800_ciaf029-B1","article-title":"WHO coronavirus (COVID-19) dashboard","author":"World Health Organization"},{"key":"2025071809220235800_ciaf029-B2","first-page":"521","article-title":"Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution","volume":"614","author":"Cao","year":"2023","journal-title":"Nature"},{"key":"2025071809220235800_ciaf029-B3","author":"World Health Organization"},{"key":"2025071809220235800_ciaf029-B4","doi-asserted-by":"crossref","first-page":"757","DOI":"10.3390\/v16050757","article-title":"COVID-19 variants and vaccine development","volume":"16","author":"Zhao","year":"2024","journal-title":"Viruses"},{"key":"2025071809220235800_ciaf029-B5","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41591-022-02185-4","article-title":"A survey of COVID-19 vaccine acceptance across 23 countries in 2022","volume":"29","author":"Lazarus","year":"2023","journal-title":"Nat Med"},{"key":"2025071809220235800_ciaf029-B6","doi-asserted-by":"crossref","first-page":"e2310650","DOI":"10.1001\/jamanetworkopen.2023.10650","article-title":"Evaluation of waning of SARS-CoV-2 vaccine-induced immunity: a systematic review and meta-analysis","volume":"6","author":"Menegale","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2025071809220235800_ciaf029-B7","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S0140-6736(22)00152-0","article-title":"Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression","volume":"399","author":"Feikin","year":"2022","journal-title":"Lancet"},{"key":"2025071809220235800_ciaf029-B8","author":"IDSA Guidelines on the Treatment and Management of Patients with COVID-19"},{"key":"2025071809220235800_ciaf029-B9","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/ohn.278","article-title":"Postmarketing reporting of Paxlovid-related dysgeusia: a real-world pharmacovigilance study","volume":"169","author":"Cvancara","year":"2023","journal-title":"Otolaryngol Head Neck Surg"},{"key":"2025071809220235800_ciaf029-B10","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.7326\/M23-1756","article-title":"SARS-CoV-2 virologic rebound with nirmatrelvir-ritonavir therapy: an observational study","volume":"176","author":"Edelstein","year":"2023","journal-title":"Ann Intern Med"},{"key":"2025071809220235800_ciaf029-B11","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/d41586-022-04576-6","article-title":"COVID drug Paxlovid was hailed as a game-changer. What happened?","volume":"613","author":"Kozlov","year":"2023","journal-title":"Nature"},{"key":"2025071809220235800_ciaf029-B12","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/cpt.2646","article-title":"Recommendations for the management of drug-drug interactions between the COVID-19 antiviral nirmatrelvir\/ritonavir (Paxlovid) and comedications","volume":"112","author":"Marzolini","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"2025071809220235800_ciaf029-B13","author":"National Institute of Health (NIH)"},{"key":"2025071809220235800_ciaf029-B14","author":"LAGEVRIO\u2122"},{"key":"2025071809220235800_ciaf029-B15","author":"Pfizer Inc"},{"key":"2025071809220235800_ciaf029-B16","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1473-3099(23)00070-1","article-title":"Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate","volume":"23","author":"Uraki","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"2025071809220235800_ciaf029-B17","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.bbrc.2023.01.040","article-title":"Ensitrelvir is effective against SARS-CoV-2 3CL protease mutants circulating globally","volume":"645","author":"Kawashima","year":"2023","journal-title":"Biochem Biophys Res Commun"},{"key":"2025071809220235800_ciaf029-B18","doi-asserted-by":"crossref","first-page":"eabq4064","DOI":"10.1126\/scitranslmed.abq4064","article-title":"S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters","volume":"15","author":"Sasaki","year":"2023","journal-title":"Sci Transl Med"},{"key":"2025071809220235800_ciaf029-B19","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41586-022-04856-1","article-title":"Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2","volume":"607","author":"Uraki","year":"2022","journal-title":"Nature"},{"key":"2025071809220235800_ciaf029-B20","doi-asserted-by":"crossref","first-page":"6499","DOI":"10.1021\/acs.jmedchem.2c00117","article-title":"Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19","volume":"65","author":"Unoh","year":"2022","journal-title":"J Med Chem"},{"key":"2025071809220235800_ciaf029-B21","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1093\/cid\/ciac933","article-title":"Efficacy and safety of ensitrelvir in patients with mild-to-moderate coronavirus disease 2019: the phase 2b part of a randomized, placebo-controlled, phase 2\/3 study","volume":"76","author":"Mukae","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025071809220235800_ciaf029-B22","doi-asserted-by":"crossref","first-page":"e0069722","DOI":"10.1128\/aac.00697-22","article-title":"A randomized phase 2\/3 study of ensitrelvir, a novel oral SARS-CoV-2 3C-like protease inhibitor, in Japanese patients with mild-to-moderate COVID-19 or asymptomatic SARS-CoV-2 infection: results of the phase 2a part","volume":"66","author":"Mukae","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2025071809220235800_ciaf029-B23","doi-asserted-by":"crossref","first-page":"e2354991","DOI":"10.1001\/jamanetworkopen.2023.54991","article-title":"Efficacy and safety of 5-day oral ensitrelvir for patients with mild to moderate COVID-19: the SCORPIO-SR randomized clinical trial","volume":"7","author":"Yotsuyanagi","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2025071809220235800_ciaf029-B24","doi-asserted-by":"crossref","first-page":"105958","DOI":"10.1016\/j.antiviral.2024.105958","article-title":"Prevention of post COVID-19 condition by early treatment with ensitrelvir in the phase 3 SCORPIO-SR trial","volume":"229","author":"Yotsuyanagi","year":"2024","journal-title":"Antiviral Res"},{"key":"2025071809220235800_ciaf029-B25","author":"US Food and Drug Administration"},{"key":"2025071809220235800_ciaf029-B26","doi-asserted-by":"crossref","first-page":"104474","DOI":"10.1016\/j.jcv.2020.104474","article-title":"Validation and verification of the Abbott RealTime SARS-CoV-2 assay analytical and clinical performance","volume":"129","author":"Degli-Angeli","year":"2020","journal-title":"J Clin Virol"},{"key":"2025071809220235800_ciaf029-B27","author":"Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events [Corrected Version 2.1 July 2017]"},{"key":"2025071809220235800_ciaf029-B28","doi-asserted-by":"crossref","first-page":"ofac492-994","DOI":"10.1093\/ofid\/ofac492.994","article-title":"1156. Sustained alleviation and resolution of targeted COVID-19 symptoms with nirmatrelvir\/ritonavir versus placebo","volume":"9","author":"Hammond","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2025071809220235800_ciaf029-B29","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1093\/cid\/ciad409","article-title":"Impact of molnupiravir treatment on patient-reported COVID-19 symptoms in the phase 3 MOVe-OUT trial: a randomized, placebo-controlled trial","volume":"77","author":"Guan","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025071809220235800_ciaf029-B30","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa2301425","article-title":"Oral simnotrelvir for adult patients with mild-to-moderate COVID-19","volume":"390","author":"Cao","year":"2024","journal-title":"N Engl J Med"},{"key":"2025071809220235800_ciaf029-B31","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0140-6736(22)02597-1","article-title":"Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial","volume":"401","author":"Butler","year":"2023","journal-title":"Lancet"},{"key":"2025071809220235800_ciaf029-B32","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N Engl J Med"},{"key":"2025071809220235800_ciaf029-B33","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1056\/NEJMoa2309003","article-title":"Nirmatrelvir for vaccinated or unvaccinated adult outpatients with COVID-19","volume":"390","author":"Hammond","year":"2024","journal-title":"N Engl J Med"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaf029\/61921470\/ciaf029.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/80\/6\/1235\/61921470\/ciaf029.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/80\/6\/1235\/61921470\/ciaf029.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T13:22:19Z","timestamp":1752844939000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/80\/6\/1235\/8017725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,17]]},"references-count":33,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,2,17]]},"published-print":{"date-parts":[[2025,7,18]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaf029","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6,15]]},"published":{"date-parts":[[2025,2,17]]}}}